Key Developments: Celgene Corp (CELG.O)

CELG.O on Nasdaq

86.97USD
11:39am EDT
Price Change (% chg)

$-0.17 (-0.20%)
Prev Close
$87.15
Open
$86.61
Day's High
$87.85
Day's Low
$86.35
Volume
1,885,073
Avg. Vol
4,883,805
52-wk High
$90.50
52-wk Low
$65.76

Search Stocks

Latest Key Developments (Source: Significant Developments)

Celgene Corporation acquires Late-Stage Product for Crohn's Disease and Other Gastrointestinal Disorders
Thursday, 24 Apr 2014 07:30am EDT 

Celgene Corporation:Enters into global license agreement with Nogra Pharma Limited to develop and commercialize GED-0301, an oral antisense DNA oligonucleotide targeting Smad7 mRNA for treatment of moderate-to-severe Crohn's disease and other indications.Nogra Pharma Limited will receive upfront payment of $710 mln, regulatory, development and net sales milestone payments and tiered royalties.Aggregate payments for regulatory and development milestones could potentially be $815 mln for multiple indications.  Full Article

Celgene Corp announces expansive multi-year strategic alliance with FORMA Therapeutics
Tuesday, 1 Apr 2014 07:30am EDT 

FORMA Therapeutics:Says a second strategic collaboration and option agreement with Celgene Corp.New collaboration will enable FORMA to extend its capabilities across broad areas of chemistry and biology.FORMA received an upfront cash payment of $225 million, and the parties entered into a collaboration with a term of 3 ½ years.  Full Article

Celgene Corp and Acceleron Pharma Inc collaborators publishes Nature Medicine Describing Sotatercept and ACE-536 Therapeutic Potential in Beta-thalassemia and Myelodysplastic Syndromes
Monday, 24 Mar 2014 07:30am EDT 

Celgene Corp and Acceleron Pharma Inc:Publication of two papers available online and in April issue of journal Nature Medicine that describe how sotatercept and ACE-536 promote red blood cell formation through an erythropoietin (EPO) independent mechanism in mice.EPO stimulates proliferation of early-stage red blood cell precursors to form new red blood cells.However, anemias associated with defects in the late-stages of red blood cell formation, known as ineffective erythropoiesis, are resistant to EPO treatment.These studies suggest that sotatercept and ACE-536 may promote and regulate maturation of late-stage red blood cell precursors.This distinct activity supports rationale for sotatercept and ACE-536 as potential novel therapies to correct anemia, including EPO-resistant anemia, in diseases such as beta-thalassemia and myelodysplastic syndromes.  Full Article

Celgene Corp announces FDA approval of OTEZLA
Friday, 21 Mar 2014 03:40pm EDT 

Celgene Corp:Says the U.S. Food and Drug Administration (FDA) approves OTEZLA, the company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), for the treatment of adult patients with active psoriatic arthritis.  Full Article

Celgene Corp reaffirms lon term outlook - Conference Call
Tuesday, 4 Mar 2014 11:20am EST 

Celgene Corp:Says it has talked about moving product sales to that $13 -$14 bln range with EPS in the $15 range by FY 2017, significant compounded annual growth.FY 2017 revenue of $13 bln, EPS of $15 - Thomson Reuters I/B/E/S.  Full Article

Health Canada approves Celgene Corp's POMALYST patients with progressive multiple myeloma
Tuesday, 11 Feb 2014 06:30am EST 

Celgene Corp:Says Health Canada has approved POMALYST oral therapy in combination with dexamethasone, for patients with multiple myeloma for whom both lenalidomide and bortezomib have failed, who have received at least two prior treatment regimens and have demonstrated disease progression on their last regimen.POMALYST received priority review status by Health Canada due to the high unmet medical need that exists and the clinical value that the treatment brings to patients and physicians.The Health Canada approval of POMALYST was based on the MM-003 pivotal study, which was published in The Lancet Oncology in Oct 2013.POMALYST is expected to be commercially available in Mar.POMALYST is a trademark of the company.  Full Article

Celgene Corp reaffirms long term outlook - Conference Call
Thursday, 30 Jan 2014 09:00am EST 

Celgene Corp:Updated long-term targets to now see revenues in a range of $13 -$14 bln in FY 2017, and EPS of at least $15.00.  Full Article

Celgene Corp reaffirms FY 2014 guidance
Thursday, 30 Jan 2014 07:32am EST 

Celgene Corp:Affirms fiscal 2014 guidance.Says fiscal 2014 total revenue expected to be about $7.5 billion, an increase of 15 percent year-over-year.Says fiscal 2014 adjusted diluted EPS expected to be in the range of $7.00 to $7.20.Says fiscal 2014 GAAP diluted EPS is expected to be in the range of $5.54 to $5.92.Fiscal 2014 revenue of $7.5 bln - Thomson Reuters I/B/E/S.  Full Article

Celgene Corp updates on FY 2013 guidance; gives FY 2014 guidance in line with analysts' estimates
Monday, 13 Jan 2014 12:00pm EST 

Celgene Corp:Says FY 2013 total revenue to be about $6.5 billion and total net product sales are expected to be $6.4 billion.Says FY 2013 adjusted diluted earnings per share (EPS) is expected to be about $5.96.Says FY 2013 based on U.S. Generally Accepted Accounting Principles (GAAP), diluted EPS is expected to be in the range of $3.37 to $3.39.Says FY 2014 total net product sales are expected to be $7.3 billion to $7.4 billion.Says FY 2014 adjusted diluted EPS to be $7.00 to $7.20.Says FY 2014 on a GAAP basis, diluted EPS is expected to be in the range of $5.54 to $5.92.FY 2013 revenue of $6.4 billion and EPS of $6.00 - Thomson Reuters I/B/E/S Estimates.FY 2014 revenue of $7.4 billion and EPS of $7.2 - Thomson Reuters I/B/E/S Estimates.  Full Article

Celgene Corp raises long term outlook - Conference Call
Monday, 13 Jan 2014 11:00am EST 

Celgene Corp:Increases estimates to a 21 pct compounded annual growth rate in product sales to $13-$14 bln and a 26 pct compounded annual growth rate going to at least $15 earnings-per-share in FY 2017.Says a year ago it talked about the 19 pct compounded annual growth in product sales that would translate over this period of FY 2017 into a 25 pct compounded annual growth rate in earnings-per-share, adjusted earnings-per-share.FY 2017 revenue of $12 bln, EPS of $14 - Thomson Reuters I/B/E/S.  Full Article

Celgene profit rises but revised outlook disappoints

- Celgene Corp reported a 25 percent rise in second-quarter profit, edging out Wall Street expectations, but a raised 2014 forecast failed to excite investors and its shares fell nearly 4 percent.

Search Stocks